You are here: Industry Insights > myovant

News List

Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval pharmatimes
July 22, 2021
Myovant Sciences and Gedeon Richter have gained an approval from the European Commission (EC) for its uterine fibroids treatment Ryeqo, the company announced 20th.
FDA approves Pfizer, Myovant’s uterine fibroids drug Myfembree pharmatimes
May 27, 2021
The US Food and Drug Administration (FDA) has approved Pfizer and Myovant’s uterine fibroids drug Myfembree for the management of heavy menstrual bleeding.
Pfizer, Myovant begin dosing in relugolix contraceptive study pharmatimes
April 15, 2021
Pfizer and Myovant have announced that dosing has begun in a Phase III study evaluating the contraceptive efficacy of their relugolix combination tablet.
Relugolix shows potential long-term benefit in women with uterine fibroids pharmatimes
March 26, 2021
Pfizer and Myovant Sciences have announced that relugolix combination therapy could have ‘potential benefit’ for the long-term treatment of women with uterine fibroids.
Myovant reports uterine fibroid combination therapy results July 25, 2019
UK healthcare company Myovant Sciences has announced positive results from LIBERTY 2, its second Phase III study of relugolix combination therapy.
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids drugs
May 20, 2019
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids.
Roivant Announces Positive Results from Myovant's LIBERTY 1 Study americanpharmaceuticalreview
May 16, 2019
Roivant subsidiary Myovant Sciences announced positive topline results from its Phase 3 LIBERTY 1 trial of relugolix combination therapy in women with uterine fibroids.
Roivant Announces Positive Results from Myovant's LIBERTY 1 Study americanpharmaceuticalreview
May 15, 2019
Roivant subsidiary Myovant Sciences announced positive topline results from its Phase 3 LIBERTY 1 trial of relugolix combination therapy in women with uterine fibroids.